Chinese Journal of Cancer Research

, Volume 4, Issue 2, pp 55–60 | Cite as

Factors influencing the effect of radioimmunotherapy on liver cancer

  • Fan Zhen 
  • Tang Zhaoyou 
  • Liu Kangda 
  • Yi Qilong 
  • Zhang Zhaohuan 
Clinical Observation


Factors influencing the therapeutic effect of radioimmunotherapy with131I labeled anti-human hepa tocellular carcinoma (HCC) ferritin antibody (131I-FtAb) on thirty three patients with surgically proven unresectable HCC were studied. Multi-variable analysis with Cox’s regression model revealed that the statistically significant factors include tumor size, activity of131I administered each time and the second-look resection. Survival of patients with tumor diameter less than 10 cm was higher than that of patients with tumor diameter more than 10 cm (1-year survival; 84% versus 50%; 3-year survival; 63% versus 9%). Patients administered with 5.55×108 Bq to 9.25×108 Bq of131I-FtAb each time yielded better effect than those administered with more than 9. 25×108 Bq of131I-FtAb (1-year, survival; 86% ver-sus 55%; 3-year survival; 50% versus 18%). When tumor shrank, patients underwent second-look resection had a higher survival than those without receiving second-look resection (1-year survival; 80% versus 66%; 3-year survival; 80% versus 11%).


Radiat Oncol Biol Phys Tumor Diameter Tocellular Carcinoma Single Variable Analysis Multiple Modality Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Alpert E, et al. Carcino-foetal human liver ferritin. Nature 1973; 242:194.PubMedCrossRefGoogle Scholar
  2. 2.
    1986; 96:6.Google Scholar
  3. 3.
    Tang ZY, et al. Tumor imaging and targeting therapy for hepatocellular carcinoma — preliminary results of experimental and clinical studies. Chinese Med J 1986; 99:855.Google Scholar
  4. 4.
    1990; 17:405.Google Scholar
  5. 5.
    Order SE, et al.131I antiferritin, a new treatment modality in hepatoma: A radiation oncology group study. J Clin Oncol 1985; 3: 1375.Google Scholar
  6. 6.
    Order SE, et al.90Y anti-ferritin — a new therapeutic radiolabeled antibody. Int J Radiat Oncol Biol Phys 1986; 12:277.PubMedGoogle Scholar
  7. 7.
    Sitzmann JV, et al. Conversion by new treatment modalities of nonresectable to resectable hepatocellular cancer. J Clin Oncol 1987; 5:1566.PubMedGoogle Scholar
  8. 8.
    Leichner PK, et al. Dosimetry of131I labeled antiferritin in hepatoma: specific activities in the tumor and liver. Cancer Treat Rep 1983; 67:647.PubMedGoogle Scholar
  9. 9.
    Leichner PK, et al. Dosimetry and treatment planning for90Y labeled antiferritin in hepatoma. Int J Radiat Oncol Biol Phys 1988; 14:1033.PubMedGoogle Scholar
  10. 10.
    Leichner PK, et al. Dosimetry and treatment planning in radioimmunotherapy. Front Radiat Ther Oncol 1990; 24:109.PubMedGoogle Scholar
  11. 11.
    Liu KD, et al. Radioimmunotherapy for hepatocellular carcinoma (HCC) using131I HCC isoferritin IgG: preliminary results of experimental and clinical studies. Int J Radiat Oncol Biol Phys 1989; 16:319.PubMedGoogle Scholar
  12. 12.
    Tang ZY, et al. Radioimmunotherapy in the multimodality treatment of hepato cellular carcinoma with reference to second look resection. Cancer 1990; 65:211.PubMedCrossRefGoogle Scholar
  13. 13.
    Cox DR, et al. Regression models and life tables. J R Statist Soc B 1972; 34:187.Google Scholar
  14. 14.
    Kaplan EL, et al. Non parametric estimation from incomplete observations. J Am Statist Assoc 1958; 53:457.CrossRefGoogle Scholar
  15. 15.
    1990; 12:2.Google Scholar
  16. 16.
    Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Research 1990(suppl); 50:814.Google Scholar
  17. 17.
    Stickney DR, et al. Enhancement of monoclonal antibody binding to melanoma with single dose irradiation or hyperthermia. Cancer Drug Del 1985; 2:225.Google Scholar
  18. 18.
    Fu KK, et al. Modification of the effects of continuous low dose rate irradiation by concurrent chemotherapy infusion. Int J Radiat Oncol Biol Phys 1984; 10:1473.PubMedGoogle Scholar
  19. 19.
    Fu KK, et al. The influence of cis-platinum administration and continuous low dose rate irradiation (CLDRI) on their combined effect on a murine squamous cell carcinoma. Int J Radiat Oncol Bio Phys 1985; 11:2119.Google Scholar
  20. 20.
    Blumenthal RD, et al. Use of hematopoietic growth factors tocontrol myelosuppression caused by radioimmunotherapy. Cancer Research 1990(suppl); 50:100.Google Scholar

Copyright information

© Chinese Journal of Cancer Research 1992

Authors and Affiliations

  • Fan Zhen 
    • 1
  • Tang Zhaoyou 
    • 1
  • Liu Kangda 
    • 1
  • Yi Qilong 
    • 1
    • 2
  • Zhang Zhaohuan 
    • 1
    • 2
  1. 1.Liver Cancer InstituteShanghai Medical UniversityChina
  2. 2.Department of Statistics, School of Public HealthShanghai Medical UniversityChina

Personalised recommendations